First Trust Advisors LP Has $34.02 Million Holdings in Moderna, Inc. $MRNA

First Trust Advisors LP boosted its stake in Moderna, Inc. (NASDAQ:MRNA) by 34.8% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,232,952 shares of the company’s stock after purchasing an additional 318,183 shares during the quarter. First Trust Advisors LP owned about 0.32% of Moderna worth $34,017,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in MRNA. S Bank Fund Management Ltd acquired a new position in shares of Moderna during the 1st quarter worth about $25,000. Rothschild Investment LLC boosted its stake in Moderna by 94.1% during the 2nd quarter. Rothschild Investment LLC now owns 920 shares of the company’s stock worth $25,000 after acquiring an additional 446 shares during the last quarter. Atlantic Union Bankshares Corp bought a new position in Moderna during the 2nd quarter worth approximately $26,000. TD Private Client Wealth LLC grew its holdings in Moderna by 348.8% during the second quarter. TD Private Client Wealth LLC now owns 956 shares of the company’s stock valued at $26,000 after purchasing an additional 743 shares during the period. Finally, Whittier Trust Co. bought a new stake in Moderna in the second quarter valued at approximately $28,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Trading Up 1.0%

Shares of MRNA opened at $28.24 on Wednesday. The stock has a market capitalization of $11.03 billion, a price-to-earnings ratio of -3.50 and a beta of 1.11. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $48.92. The firm has a fifty day simple moving average of $25.97 and a 200 day simple moving average of $27.00.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($2.15) by $1.64. Moderna had a negative net margin of 139.61% and a negative return on equity of 29.81%. The firm had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $893.29 million. During the same period in the previous year, the firm posted $0.03 EPS. The company’s revenue for the quarter was down 45.4% on a year-over-year basis. As a group, research analysts predict that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on MRNA. Citigroup reduced their price target on shares of Moderna from $30.00 to $28.00 and set a “neutral” rating on the stock in a research report on Thursday, October 23rd. Bank of America reduced their target price on Moderna from $24.00 to $21.00 and set an “underperform” rating on the stock in a report on Monday, November 10th. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research note on Monday, October 20th. Royal Bank Of Canada lowered their price target on Moderna from $28.00 to $25.00 and set a “sector perform” rating for the company in a report on Friday, November 21st. Finally, JPMorgan Chase & Co. cut their price objective on Moderna from $26.00 to $25.00 and set an “underweight” rating on the stock in a report on Thursday, October 23rd. Two analysts have rated the stock with a Buy rating, twelve have given a Hold rating and five have given a Sell rating to the stock. According to MarketBeat, Moderna currently has a consensus rating of “Reduce” and an average target price of $29.46.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.